RhoA Drives T-Cell Activation and Encephalitogenic Potential in an Animal Model of Multiple Sclerosis

被引:0
作者
Manresa-Arrauti, Alba [1 ]
Johansen, Flemming Fryd [1 ]
Brakebusch, Cord [2 ]
Issazadeh-Nayikas, Shohreh [1 ]
Hasseldam, Henrik [1 ]
机构
[1] Univ Copenhagen, Fac Hlth & Med Sci, BRIC, Neuroinfiammat Unit, Copenhagen, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Cytoskeletal Org Grp, BRIC, Copenhagen, Denmark
关键词
RhoA; multiple sclerosis; experimental autoimmune encephalomyelitis; T-cell; neuroinflammation; KINASE ROCK INHIBITORS; INTERFERON BETA-1A; DOUBLE-BLIND; GTPASE RHO; CONTROLLED-TRIAL; MIGRATION; POLARIZATION; NATALIZUMAB; RECEPTOR; THERAPY;
D O I
10.3389/timrnu.2018.01235
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T-cells are known to be intimately involved in the pathogenesis of multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). T-cell activation is controlled by a range of intracellular signaling pathways regulating cellular responses such as proliferation, cytokine production, integrin expression, and migration. These processes are crucial for the T-cells' ability to mediate inflammatory processes in autoimmune diseases such as MS. RhoA is a ubiquitously expressed small GTPase well described as a regulator of the actin cytoskeleton. It is essential for embryonic development and together with other Rho GTPases controls various cellular processes such as cell development, shaping, proliferation, and locomotion. However, the specific contribution of RhoA to these processes in T-cells in general, and in auto reactive T-cells in particular, has not been fully characterized. Using mice with a T-cell specific deletion of the RhoA gene (RhoA(fi/fi)/LckCre(+)), we investigated the role of RhoA in T-cell development, functionality, and encephalitogenic potential in EAE. We show that lack of RhoA specifically in T-cells results in reduced numbers of mature T-cells in thymus and spleen but normal counts in peripheral blood. EAE induction in RhoA(fi/fi) LckCre(+) mice results in significantly reduced disease incidence and severity, which coincides with a reduced CNS T-cell infiltration. Besides presenting reduced migratory capacity, both naive and autoreactive effector T-cells from RhoA(fi/fi)Lckere mice show decreased viability, proliferative capacity, and an activation profile associated with reduced production of Thl pro-inflammatory cytokines. Our study demonstrates that RhoA is a central regulator of several archetypical T-cell responses, and furthermore points toward RhoA as a new potential therapeutic target in diseases such as MS, where T-cell activity plays a central role.
引用
收藏
页数:14
相关论文
共 49 条
[1]   Drugs in Development for Relapsing Multiple Sclerosis [J].
Ali, Rehiana ;
Nicholas, Richard St John ;
Muraro, Paolo Antonio .
DRUGS, 2013, 73 (07) :625-650
[2]   Involvement of the MAPK and RhoA/ROCK pathways in PGE2-mediated CCR7-dependent monocyte migration [J].
Allaire, Marc-Andre ;
Dumais, Nancy .
IMMUNOLOGY LETTERS, 2012, 146 (1-2) :70-73
[3]   QuPath: Open source software for digital pathology image analysis [J].
Bankhead, Peter ;
Loughrey, Maurice B. ;
Fernandez, Jose A. ;
Dombrowski, Yvonne ;
Mcart, Darragh G. ;
Dunne, Philip D. ;
McQuaid, Stephen ;
Gray, Ronan T. ;
Murray, Liam J. ;
Coleman, Helen G. ;
James, Jacqueline A. ;
Salto-Tellez, Manuel ;
Hamilton, Peter W. .
SCIENTIFIC REPORTS, 2017, 7
[4]   Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes [J].
Bardi, G ;
Niggli, V ;
Loetscher, P .
FEBS LETTERS, 2003, 542 (1-3) :79-83
[5]   Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis [J].
Bargiela, David ;
Bianchi, Matthew T. ;
Westover, M. Brandon ;
Chibnik, Lori B. ;
Healy, Brian C. ;
De Jager, Philip L. ;
Xia, Zongqi .
NEUROLOGY, 2017, 88 (07) :677-684
[6]   Targeting Rho-GTPases in immune cell migration and inflammation [J].
Biro, Mate ;
Munoz, Marcia A. ;
Weninger, Wolfgang .
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (24) :5491-5506
[7]   Ingested (oral) anti-IL-12/23 inhibits EAE [J].
Brod, Staley A. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 361 :19-25
[8]   Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study [J].
Calabresi, Peter A. ;
Kieseier, Bernd C. ;
Arnold, Douglas L. ;
Balcer, Laura J. ;
Boyko, Alexey ;
Pelletier, Jean ;
Liu, Shifang ;
Zhu, Ying ;
Seddighzadeh, All ;
Hung, Serena ;
Deykin, Aaron .
LANCET NEUROLOGY, 2014, 13 (07) :657-665
[9]   Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial [J].
Coles, A. J. ;
Fox, E. ;
Vladic, A. ;
Gazda, S. K. ;
Brinar, V. ;
Selmaj, K. W. ;
Skoromets, A. ;
Stolyarov, I. ;
Bass, A. ;
Sullivan, H. ;
Margolin, D. H. ;
Lake, S. L. ;
Moran, S. ;
Palmer, J. ;
Smith, M. S. ;
Compston, D. A. S. .
NEUROLOGY, 2012, 78 (14) :1069-1078
[10]   Multiple sclerosis [J].
Compston, Alastair ;
Coles, Alasdair .
LANCET, 2008, 372 (9648) :1502-1517